Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) Overview
Pro stress-test →Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics, with its most advanced clinical candidate being DKN-01 (sirexatamab), a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein being developed in patients with esophagogastric, gynecologic, and colorectal cancers. In November 2025, the company rebranded to Cypherpunk Technologies Inc. and began trading under the ticker CYPH while continuing cancer drug development through a subsidiary carrying the Leap Therapeutics name.
Strategic Profile
Pro stress-test →The company completed a $58.88 million private placement in October 2025 and deployed approximately $50 million to acquire Zcash (ZEC) as part of a new digital asset treasury strategy alongside its oncology pipeline. Leap showcases a strong clinical outlook with sirexatamab demonstrating a notable 39% objective response rate in patients with elevated DKK1 levels, positioning the company to engage with the FDA for potential regulatory pathway advancement.
Competitive Landscape
Pro stress-test →Leap operates in the targeted and immuno-oncology therapeutics space, competing against larger established players in monoclonal antibody development for solid tumors. The company's differentiation relies on specific DKK1 and Claudin18.2 targeting mechanisms with early clinical data, but faces intense competition from well-capitalized oncology biotech firms and Big Pharma programs in similar indications.
Industry Context
Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) operates in Biopharmaceutical / Oncology Therapeutics.
Key facts
Founded: 2011 · Headquarters: Cambridge, Massachusetts · Market cap: $24.8M